Trials to overcome drug resistance to EGFR and ALK targeted therapies - past, present and future
Molecularly targeted agents (MTAs) are changing the therapeutic landscape in advanced non-small cell lung cancer (NSCLC). Since the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) domain, clinical investigations have focused on...
Main Authors: | Glenwood Dillon Goss, Johanna eSpaans |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00233/full |
Similar Items
-
Drug Resistance to molecular targeted therapy and its consequences for the treatment decisions in non-small-cell lung cancer
by: Johanna N Spaans, et al.
Published: (2014-07-01) -
Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer
by: Xin WANG, et al.
Published: (2018-09-01) -
From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
by: Michael T. Werner, et al.
Published: (2017-10-01) -
A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-rearranged Non-Small Cell Lung Cancer
by: Khashayar eEsfahani, et al.
Published: (2014-07-01) -
Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma
by: Kai Yin, et al.
Published: (2020-02-01)